244 related articles for article (PubMed ID: 33150172)
1. Pharmacogenetic Association between
Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
[TBL] [Abstract][Full Text] [Related]
2. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.
Cui Z; Yin Z; Li X; Wu W; Guan P; Zhou B
BMC Cancer; 2012 Feb; 12():71. PubMed ID: 22339849
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
5. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
[TBL] [Abstract][Full Text] [Related]
6. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.
Yuan Z; Li J; Hu R; Jiao Y; Han Y; Weng Q
Sci Rep; 2015 Nov; 5():16482. PubMed ID: 26585370
[TBL] [Abstract][Full Text] [Related]
7. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
[TBL] [Abstract][Full Text] [Related]
10. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
[TBL] [Abstract][Full Text] [Related]
11. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
12. X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.
Wu H; Xu C; Chen G; Wang J
J Gastroenterol Hepatol; 2014 May; 29(5):926-33. PubMed ID: 24224851
[TBL] [Abstract][Full Text] [Related]
13. Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population.
Wu D; Jiang H; Gu Q; Zhang D; Li Z
Tumour Biol; 2013 Oct; 34(5):3265-9. PubMed ID: 23780894
[TBL] [Abstract][Full Text] [Related]
14. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
Tan LM; Qiu CF; Zhu T; Jin YX; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jul; 7(1):5593. PubMed ID: 28717179
[TBL] [Abstract][Full Text] [Related]
15. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
Chen J; Zhao QW; Shi GM; Wang LR
J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
[TBL] [Abstract][Full Text] [Related]
16. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Valdivia-Bautista J; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics J; 2019 Apr; 19(2):164-177. PubMed ID: 29662106
[TBL] [Abstract][Full Text] [Related]
18. The XRCC1 Arg194Trp polymorphism was associated with the risk of head and neck squamous cell carcinoma development: Results from a systematic review and meta-analysis.
Mohtasham N; Najafi-Ghobadi K; Abbaszadeh H
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1776. PubMed ID: 36573562
[TBL] [Abstract][Full Text] [Related]
19. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
Liu HF; Liu JS; Deng JH; Wu RR
Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
[TBL] [Abstract][Full Text] [Related]
20. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.
Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H
Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
